for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Immunovia AB (publ)

IMMNOV.ST

Latest Trade

132.80SEK

Change

-7.00(-5.01%)

Volume

9,406

Today's Range

132.80

 - 

140.60

52 Week Range

118.00

 - 

188.80

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Immunovia Q3 Net Loss Widens To SEK 25.6 Mln

Nov 8 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::IMMUNOVIA INTERIM REPORT, JANUARY-SEPTEMBER 2019.Q3 NET SALES SEK 92,000 VERSUS SEK 85,000 YEAR AGO.Q3 NET LOSS SEK 25.6 MILLION VERSUS LOSS SEK 17.4 MILLION YEAR AGO.WE REMAIN FULLY COMMITTED AND FOCUSED ON IMMRAY PANCAN-D.WE CONTINUE TO BE ON-SCHEDULE AND WORK INTENSELY FOR ALL PREPARATIONS FOR OUR PLANNED LAUNCH OF IMMRAY PANCAN-D IN Q3 2020.BRINGING IMMRAY PANCAN-D TO MARKET AND DOMINATING MARKET FOR EARLY DETECTION OF PANCREATIC CANCER IN FORESEEABLE FUTURE IS AN OPPORTUNITY WITH TOTAL ESTIMATED MARKET POTENTIAL OF USD 4.4 BILLION IN US AND EUROPE ALONE, AND IS NOW WITHIN OUR REACH.

Immunovia Q2 Loss Before Tax Widens To SEK 29.9 Million

Aug 23 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::Q2 NET SALES SEK 154,000 VERSUS SEK 44,000 YEAR AGO.Q2 LOSS BEFORE TAX 29.9 MILLION VERSUS LOSS SEK 26,1 MILLION YEAR AGO.IMMRAY PANCAN-D, CO'S BLOOD-BASED TEST FOR EARLY DETECTION OF PANCREATIC CANCER, IS NOW SET FOR Q3 2020 LAUNCH.

Immunovia and Erlangen University Hospital Enter Into A Collaboration Agreement

July 17 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::ERLANGEN UNIVERSITY HOSPITAL AND IMMUNOVIA ENTER INTO A COLLABORATION AGREEMENT FOR THE COLLECTION OF PANCREATIC CANCER BLOOD SAMPLES FOR THE FINAL STEPS OF IMMRAY™ PANCAN-D DEVELOPMENT.ERLANGEN UNIVERSITY HOSPITAL BECOMES FIRST CANCER CENTER IN GERMANY TO JOIN CO'S GLOBAL NETWORK OF KEY OPINION LEADERS IN QUEST FOR EARLY DIAGNOSIS OF PANCREATIC CANCER.ERLANGEN UNIVERSITY HOSPITAL WILL, IN ADDITION TO CO'S ALREADY EXISTING COLLABORATIONS, SUPPLY BLOOD SAMPLES FOR FINAL TWO STEPS TO MARKET OF IMMRAY.

Immunovia's CEO Sells 48,000 Immunovia Shares

June 19 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::IMMUNOVIA'S CEO MATS GRAHN SELLS 48,000 IMMUNOVIA SHARES TO A SWEDISH INSTITUTIONAL INVESTOR.TRANSACTION WAS CARRIED OUT AT A PRICE OF SEK 168 PER SHARE.MATS GRAHN, CEO OF IMMUNOVIA, TODAY ANNOUNCED THAT HE HAS SOLD 48,000 SHARES OF IMMUNOVIA, CORRESPONDING TO 11.6% OF HIS HOLDING IN IMMUNOVIA.

Immunovia Appoints Pete Salzmann As CEO

June 5 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::IMMUNOVIA AB (PUBL) - APPOINTS PETE SALZMANN AS CHIEF EXECUTIVE OFFICER.

Immunovia Announces Results From Immray PanCan-D Optimization Work

June 3 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::IMMUNOVIA ANNOUNCES EXCELLENT RESULTS ACROSS ALL SYMPTOMATIC RISK GROUPS FROM IMMRAY PANCAN-D OPTIMIZATION WORK.IMMRAY PANCAN-D BLOOD-BASED TEST FOR EARLY DETECTION OF PANCREATIC CANCER NOW SET FOR Q3 2020 LAUNCH.OPTIMIZATION WORK FOR COMMERCIAL VERSION OF IMMRAY PANCAN-D BEEN SUCCESSFUL AND SIGNIFICANTLY IMPROVED PERFORMANCE OF TEST.TEST NOW SHOWS ACCURACIES HIGHER THAN 90% AND EVEN UP TO 98% IN DIFFERENTIATING PDAC OF STAGE I THROUGH IV VERSUS LARGE SYMPTOMATIC RISK GROUPS.

Immunovia: Additional US Centers To Validate Immraytm Pancan-D Test Designed

May 16 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::IMMUNOVIA - CENTERS IN NEW YORK AND CHICAGO TO VALIDATE IMMRAYTM PANCAN-D TEST DESIGNED FOR EARLY DETECTION OF PANCREATIC CANCER.

Immunovia Q1 Operating Earnings Loss Widens To SEK 27.2 Million

April 24 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::Q1 NET SALES SEK 66,000 VERSUS SEK 112,000 YEAR AGO.COMPANY REITERATES IT'S FINANCIAL TARGETS.COMPANY ANTICIPATES FIRST REVENUES FROM SELF PAY SALES IN EARLY 2020.Q1 OPERATING EARNINGS LOSS SEK 27.2 MILLION VERSUS LOSS SEK 17.4 MILLION YEAR AGO.

Immunovia Advances Strategic Collaboration With Primary Care Physicians In US

April 12 (Reuters) - Immunovia AB (publ) <IMMNOV.ST>::IMMUNOVIA ADVANCES STRATEGIC COLLABORATION WITH PRIMARY CARE PHYSICIANS IN THE US TO BUILD AWARENESS OF THE IMPORTANCE OF EARLY DETECTION OF PANCREATIC CANCER.CONTINUED COMMITMENT TO ITS STRATEGIC INITIATIVE OF COLLABORATING WITH PRIMARY CARE PHYSICIANS (PCPS) IN US.

Immunovia Q4 Pretax Loss Widens To SEK 25.7 Mln

Feb 15 (Reuters) - Immunovia AB <IMMNOV.ST>::REPORTED ON THURSDAY Q4 NET SALES SEK 91,000 VS SEK 26,000 YR AGO.Q4 PRETAX LOSS SEK 25.7 MLN VS LOSS SEK 15.3 MLN YR AGO.CO'S FINANCIAL TARGETS REMAIN IN PLACE FROM THE PREVIOUS QUARTER.EXPECTS TO RECEIVE THE FIRST REVENUES FROM SELF-PAY SALES IN THE LATTER PART OF 2019.TARGET IS TO ACHIEVE TURNOVER OF SEK 250-300 MILLION BY 2022 BASED ON SELF-PAY FOR IMMRAY PANCAN–D.TARGET IS TO ACHIEVE TOTAL TURNOVER, INCLUDING PAYMENT VIA SELF-PAY AND COST REMUNERATION FROM INSURANCE SYSTEMS, OF SEK 800-1,000 MILLION BY 2024.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up